Recently, meta-analyses strongly supported the prognostic and clinicopathological relevance of CXCR4 in breast, esophageal, colorectal, gastric, and ovarian cancer, as well as in renal cell carcinomas and gliomas [47–53]. Here, CXCR4 is linked to ovarian cancer.